Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'
Research Report

Share on Stocktwits


André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) reported that in preclinical studies, its asset, PMN310, demonstrated no "binding to amyloid beta plaques in and around blood vessels in human and rodent Alzheimer's brain samples," wrote Mackie Research Capital Corp. analyst André Uddin in a Jan. 4, 2018, research note.

This result is a "positive indicator of improved safety for Alzheimer's drugs, as amyloid beta plaque binding is believed to be associated with dose-limiting brain swelling and microhemorrhages," Uddin explained.

Whereas PMN310 hasn't shown plaque binding, Biogen's aducanumab and Pfizer/Johnson & Johnson's bapineuzumab have, Uddin noted, "suggesting PMN310 could have an improved safety profile" over that of those drugs and as such, "should facilitate a potential licensing deal for PMN310." Mackie expects such a partnership could happen as early as sometime this year, but to be conservative, in its company model it is using 2019 instead.

Uddin reiterated that ProMIS Neurosciences remains a "high-risk, high-reward opportunity." He added, "Based on currently available data and our extensive due diligence, we believe PMN310 should be better than Biogen's aducanumab and should have the best-in-class potential to treat Alzheimer's."

Mackie has a Speculative Buy rating and a CA$0.50 per share target price on ProMIS, whose stock is currently trading at around $0.23 per share.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neursciences Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures

Disclosures from Mackie Research Capital Corp., ProMIS Neurosciences Inc., Update, Jan. 4, 2018

Relevant disclosures required under IIROC Rule 3400 applicable to companies under coverage discussed in this research report are available on our web site at

Each analyst of Mackie Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst's personal views and (ii) no part of the research analyst's compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe